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Letters to the Editor1184valve leaflets was restricted by the prosthetic stent resulting in
severe central regurgitation stopping at the competent biopros-
thetic leaflets. An urgent valve-in-valve TAVI was planned but
repeat TEE demonstrated further valve migration into LVOT
that precluded safe implantation of the second overlapping
prosthesis. The patient underwent an emergent open-heart
surgery during which the TAVI valve was found sitting in
LVOT in an unstable position. The native valve leaflets had 3
relatively flexible cusps with moderate calcification (Fig. 1E).
The aortic annulus had only trivial amount of calcium. The AV
was replaced with 23-mm Perimount Magna (Edwards Life-
sciences) tissue valve. The patient tolerated the surgery well.
Valve dislodgment may occur in patients with less-than-severe
AV and root calcification that may be insufficient for anchoring the
prosthesis (1,2), which was likely the case in our patient. Other
potential causes include stent malposition (3,4) and selection of an
undersized valve (5). In the present case, the correct 26-mm valve
was selected based on 23-mm annulus, and its optimal position was
confirmed with aortogram and TEE. Forces from the peripros-
thetic and central AV regurgitation, and from the residual over-
hanging native AV leaflets (2) likely contributed to the progression
of valve migration.
This case demonstrates that routine 24-h follow-up echocardi-
ography is essential to confirm correct TAVI valve position and
function in order to prevent adverse consequences of delayed
mechanical complications. In addition, it demonstrates that TAVI
should be used with caution in patients with less-than-severe AV
calcification.
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Effective Dose of PET/CT in
Informed Consent Forms
The recent article by Terranova et al. (1) made important points
about informed consent. We agree with their conclusions that “the
development of simpler and more informative informed consent
models and forms will gently force the doctor to be more aware of
what he/she does and the patient more aware of what he/she
undergoes, enabling both to make more responsible choices” (1).
However, the authors might have begun with the correct facts to
avoid the gross error shown in Figure 3. At the bottom right of that
figure, the dose for rest/stress myocardial perfusion positron emis-
sion tomography (PET) is shown as approximately 1,000 “equiva-
lent number of chest x-rays.” For a visual representation, the
authors reproduced Figure 2A from our prior publication, featured
on the cover of that issue of the Journal of Nuclear Medicine (2). As
we described in the middle of the second column on page 1,113 of
that paper (2), with further detail in Table 2 of a subsequent paper
(3), the dose equivalent from our rest/stress cardiac PET scan using
computed tomography (CT) attenuation correction is approxi-
mately 7.5 mSv (using a low-dose helical CT at rest and a single
post-stress cine CT in addition to the rubidium-82 tracer for PET).
Assuming a standard 0.02-mSv effective dose for a chest x-ray,
our PET/CT scan equals roughly 375 chest x-rays, almost one-
third of the value suggested in their Figure 3 (1). As such, PET/CT
delivers less radiation than other modalities in their Table 3:
single-photon emission computed tomography (SPECT) (using
either technetium-99m or thallium-201), CT angiogram, or per-
cutaneous coronary intervention. As an additional error, the dose-
based order of tests on the x-axis of Figure 3 (invasive angiogram,
SPECT, CT angiogram, PET) differs from their order in Table 3
above it (SPECT with technetium-99m, CT angiogram, invasive
stenting, SPECT with thallium-201). Therefore, Figure 3 was
factually incorrect and failed the authors’ words for “simpler and
more informative informed consent.”
Moreover, quantitative PET perfusion imaging is a powerful
guide to avoid the higher-dose procedures like SPECT imaging
and CT or invasive angiography by quantitatively defining physio-
logical stenosis severity before these procedures are undertaken and
identifying who will optimally benefit from them (4) at the lowest
total radiation dose.
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(1). The “factually incorrect” doses reported in Figure 3 are indeed
correct. Positron emission tomography (PET) scans are usually
coupled with angiogram computed tomography (CT) and lead
precisely to a cumulative (CT angiogram  PET scan) dose of
approximately 20 mSv (1,000 chest x-rays) (2). PET scan alone
(without CT) totals 2 mSv with 13-ammonia, and 3 mSv with
82-rubidium. Obviously, reported doses are only reference doses,
and lower doses can be achieved with state-of-the-art CT technol-
ogy. On the other hand, for each test (from CT to single-photon
emission computed tomography [SPECT] to coronary angiogra-
phy), substantially (up to 5-fold) higher doses can be recorded in
the real world—especially when no systematic dose audit is imple-
mented in the imaging laboratory (3).
We agree that a major advantage of PET myocardial perfusion
imaging is the lower radiation dose when compared with SPECT
(2 mSv vs. 8 to 10 mSv). Obviously, this advantage may apply
mainly in cost-insensitive settings in which there is no technology
or expertise for zero-dose cardiac testing with magnetic resonance
imaging or stress echocardiography—which provide similar diag-
nostic and prognostic results at much lower cost using radiation-
free techniques (4). Only an explicit, systematic discussion of costs
and risks would facilitate the identification of appropriate, sustain-
able medical imaging strategies (5), avoiding the use of high-cost,
high-risk techniques instead of low-cost, low-risk methods with
comparable benefit.
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Intraplaque Hemorrhage,
RBC-Derived Cholesterol,
and Plaque Progression
Time to Move From Conjecture to Evidence?
The interesting study by Sun et al. (1) in a recent issue of iJACC
dds important new insights into the role of intraplaque hemor-
hage (IPH) in the natural history of carotid atherosclerosis. Serial
agnetic resonance imaging (MRI) over an extended period of
bservation demonstrated that plaque growth after the occurrence
f IPH was on average higher compared with the period before
PH (1). Notably, however, the rate of individual plaque growth
iffered substantially after the occurrence of IPH; some plaques
ctually showed regression despite evidence of new IPH, as shown
n Figure 4 of Sun et al. (1). Thus, this study strongly links IPH to
ccelerated atherosclerosis, but it also raises a key issue: detection of
PH alone may be a suboptimal predictor of the exact rate and
agnitude of subsequent plaque growth. Therefore, identification
f other factors that modulate the proatherogenic effect of IPH
ight enhance the potential of MRI to accurately predict which
esions with IPH will exhibit most pronounced and rapid growth.
ased on the pathobiological sequelae of IPH (2), we suggest that
ifferences in the cholesterol contents of erythrocyte membranes
CEM) are very likely to account, at least in part, for the observed
ifferential plaque growth after IPH (1).
The driving mechanisms of plaque progression and the main
ource of cholesterol that is accumulated in the developing plaque
iffer fundamentally in lesions without versus those with IPH. In
esions without IPH, cholesterol in the plaque is derived mainly
rom circulating blood lipoproteins; hence, higher blood cholesterol
evels amplify the proatherogenic stimulus of adverse local hemo-
ynamics, which is a major driving force of focal plaque develop-
ent in this setting (3). In contrast, in lesions with IPH extrava-
ated erythrocytes contain abundant free cholesterol that is
bsorbed into the necrotic core and is conjectured to contribute
entrally to plaque enlargement (2). Accordingly, in lesions with
PH, it seems highly plausible that increasing levels of CEM might
mplify the proatherogenic stimulus of IPH per se.
Of clinical importance, the CEM can be measured in the clinic
4,5) and is positively related to coronary plaque burden (4) and
laque instability (5). We hereby propose that the combination of
EM measurement with serial MRI may substantiate our current
nderstanding of the role of IPH in plaque biology and, conse-
uently, may enhance risk-stratification of patients with evidence of
PH. First, a finding of greatest plaque progression after IPH in
atients with higher compared with those with lower CEM levels
ould lend definitive mechanistic support to the long-standing
